Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA. / Wegmann, Mathilde Gersel; Jensen, Rikke Beck; Thankamony, Ajay; Frystyk, Jan; Roche, Edna; Hoey, Hilary; Kirk, Jeremy; Shaikh, Guftar; Ivarsson, Sten-A; Söder, Olle; Dunger, David B; Juul, Anders.

I: Journal of Clinical Endocrinology and Metabolism, Bind 105, Nr. 4, 2020, s. e1291–e1298.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Wegmann, MG, Jensen, RB, Thankamony, A, Frystyk, J, Roche, E, Hoey, H, Kirk, J, Shaikh, G, Ivarsson, S-A, Söder, O, Dunger, DB & Juul, A 2020, 'Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA', Journal of Clinical Endocrinology and Metabolism, bind 105, nr. 4, s. e1291–e1298. https://doi.org/10.1210/clinem/dgz118

APA

Wegmann, M. G., Jensen, R. B., Thankamony, A., Frystyk, J., Roche, E., Hoey, H., Kirk, J., Shaikh, G., Ivarsson, S-A., Söder, O., Dunger, D. B., & Juul, A. (2020). Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA. Journal of Clinical Endocrinology and Metabolism, 105(4), e1291–e1298. https://doi.org/10.1210/clinem/dgz118

Vancouver

Wegmann MG, Jensen RB, Thankamony A, Frystyk J, Roche E, Hoey H o.a. Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA. Journal of Clinical Endocrinology and Metabolism. 2020;105(4):e1291–e1298. https://doi.org/10.1210/clinem/dgz118

Author

Wegmann, Mathilde Gersel ; Jensen, Rikke Beck ; Thankamony, Ajay ; Frystyk, Jan ; Roche, Edna ; Hoey, Hilary ; Kirk, Jeremy ; Shaikh, Guftar ; Ivarsson, Sten-A ; Söder, Olle ; Dunger, David B ; Juul, Anders. / Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA. I: Journal of Clinical Endocrinology and Metabolism. 2020 ; Bind 105, Nr. 4. s. e1291–e1298.

Bibtex

@article{b7c5a9a47e8a4226b26839881c7cbeb1,
title = "Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA",
abstract = "BACKGROUND: Some children born small for gestational age (SGA) experience supra-physiological insulin-like growth factor-I (IGF-I) concentrations during GH treatment. However, measurements of total IGF-I concentrations may not reflect the bioactive fraction of IGF-I which reaches the IGF-I receptor at target organs. We examined endogenous IGF-bioactivity using an IGF-I kinase receptor activation (KIRA) assay that measures the ability of IGF-I to activate the IGF-IR in vitro.AIM: To compare responses of bioactive IGF and total IGF-I concentrations in short GH treated SGA children in the North European Small for Gestational Age Study (NESGAS).MATERIAL AND METHOD: In NESGAS, short SGA children (n = 101, 61 males) received GH at 67 µg/kg/day for 1 year. IGF-I concentrations were measured by Immulite immunoassay and bioactive IGF by in-house KIRA assay.RESULTS: Bioactive IGF increased with age in healthy pre-pubertal children (n = 94). SGA children had low-normal bioactive IGF levels at baseline (-0.12 (1.8 SD), increasing significantly after one year of high-dose GH treatment to 1.1 (1.4) SD, P < 0.01. Following high-dose GH, 68% (n = 65) of SGA children had a total IGF-I concentration >2SD (mean IGF-I 2.8 SDS), whereas only 15% (n = 15) had levels of bioactive IGF slightly above normal reference values. At baseline, bioactive IGF (SDS) was significantly correlated to height (SDS) (r = 0.29, P = 0.005), in contrast to IGF-I (SDS) (r = 0.17, P = 0.10). IGF-I (SDS) was inversely correlated to delta height (SDS) after one year of high-dose GH treatment (r = -0.22, P = 0.02).CONCLUSION: In contrast to total IGF-I concentrations, bioactive IGF stayed within the normal reference ranges for most SGA children during the first year of GH treatment.",
keywords = "Biomarkers/blood, Body Height/drug effects, Case-Control Studies, Child, Female, Follow-Up Studies, Growth Disorders/blood, Human Growth Hormone/administration & dosage, Humans, Infant, Small for Gestational Age/blood, Insulin-Like Growth Factor Binding Protein 3/blood, Insulin-Like Growth Factor I/analysis, Male, Prognosis",
author = "Wegmann, {Mathilde Gersel} and Jensen, {Rikke Beck} and Ajay Thankamony and Jan Frystyk and Edna Roche and Hilary Hoey and Jeremy Kirk and Guftar Shaikh and Sten-A Ivarsson and Olle S{\"o}der and Dunger, {David B} and Anders Juul",
note = "{\textcopyright} Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2020",
doi = "10.1210/clinem/dgz118",
language = "English",
volume = "105",
pages = "e1291–e1298",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Increases in Bioactive IGF do not Parallel Increases in Total IGF-I During Growth Hormone Treatment of Children Born SGA

AU - Wegmann, Mathilde Gersel

AU - Jensen, Rikke Beck

AU - Thankamony, Ajay

AU - Frystyk, Jan

AU - Roche, Edna

AU - Hoey, Hilary

AU - Kirk, Jeremy

AU - Shaikh, Guftar

AU - Ivarsson, Sten-A

AU - Söder, Olle

AU - Dunger, David B

AU - Juul, Anders

N1 - © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Some children born small for gestational age (SGA) experience supra-physiological insulin-like growth factor-I (IGF-I) concentrations during GH treatment. However, measurements of total IGF-I concentrations may not reflect the bioactive fraction of IGF-I which reaches the IGF-I receptor at target organs. We examined endogenous IGF-bioactivity using an IGF-I kinase receptor activation (KIRA) assay that measures the ability of IGF-I to activate the IGF-IR in vitro.AIM: To compare responses of bioactive IGF and total IGF-I concentrations in short GH treated SGA children in the North European Small for Gestational Age Study (NESGAS).MATERIAL AND METHOD: In NESGAS, short SGA children (n = 101, 61 males) received GH at 67 µg/kg/day for 1 year. IGF-I concentrations were measured by Immulite immunoassay and bioactive IGF by in-house KIRA assay.RESULTS: Bioactive IGF increased with age in healthy pre-pubertal children (n = 94). SGA children had low-normal bioactive IGF levels at baseline (-0.12 (1.8 SD), increasing significantly after one year of high-dose GH treatment to 1.1 (1.4) SD, P < 0.01. Following high-dose GH, 68% (n = 65) of SGA children had a total IGF-I concentration >2SD (mean IGF-I 2.8 SDS), whereas only 15% (n = 15) had levels of bioactive IGF slightly above normal reference values. At baseline, bioactive IGF (SDS) was significantly correlated to height (SDS) (r = 0.29, P = 0.005), in contrast to IGF-I (SDS) (r = 0.17, P = 0.10). IGF-I (SDS) was inversely correlated to delta height (SDS) after one year of high-dose GH treatment (r = -0.22, P = 0.02).CONCLUSION: In contrast to total IGF-I concentrations, bioactive IGF stayed within the normal reference ranges for most SGA children during the first year of GH treatment.

AB - BACKGROUND: Some children born small for gestational age (SGA) experience supra-physiological insulin-like growth factor-I (IGF-I) concentrations during GH treatment. However, measurements of total IGF-I concentrations may not reflect the bioactive fraction of IGF-I which reaches the IGF-I receptor at target organs. We examined endogenous IGF-bioactivity using an IGF-I kinase receptor activation (KIRA) assay that measures the ability of IGF-I to activate the IGF-IR in vitro.AIM: To compare responses of bioactive IGF and total IGF-I concentrations in short GH treated SGA children in the North European Small for Gestational Age Study (NESGAS).MATERIAL AND METHOD: In NESGAS, short SGA children (n = 101, 61 males) received GH at 67 µg/kg/day for 1 year. IGF-I concentrations were measured by Immulite immunoassay and bioactive IGF by in-house KIRA assay.RESULTS: Bioactive IGF increased with age in healthy pre-pubertal children (n = 94). SGA children had low-normal bioactive IGF levels at baseline (-0.12 (1.8 SD), increasing significantly after one year of high-dose GH treatment to 1.1 (1.4) SD, P < 0.01. Following high-dose GH, 68% (n = 65) of SGA children had a total IGF-I concentration >2SD (mean IGF-I 2.8 SDS), whereas only 15% (n = 15) had levels of bioactive IGF slightly above normal reference values. At baseline, bioactive IGF (SDS) was significantly correlated to height (SDS) (r = 0.29, P = 0.005), in contrast to IGF-I (SDS) (r = 0.17, P = 0.10). IGF-I (SDS) was inversely correlated to delta height (SDS) after one year of high-dose GH treatment (r = -0.22, P = 0.02).CONCLUSION: In contrast to total IGF-I concentrations, bioactive IGF stayed within the normal reference ranges for most SGA children during the first year of GH treatment.

KW - Biomarkers/blood

KW - Body Height/drug effects

KW - Case-Control Studies

KW - Child

KW - Female

KW - Follow-Up Studies

KW - Growth Disorders/blood

KW - Human Growth Hormone/administration & dosage

KW - Humans

KW - Infant, Small for Gestational Age/blood

KW - Insulin-Like Growth Factor Binding Protein 3/blood

KW - Insulin-Like Growth Factor I/analysis

KW - Male

KW - Prognosis

U2 - 10.1210/clinem/dgz118

DO - 10.1210/clinem/dgz118

M3 - Journal article

C2 - 31665326

VL - 105

SP - e1291–e1298

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 259057706